Diagnosis and Drug Therapy of Prolactinoma

@article{Ciccarelli2012DiagnosisAD,
  title={Diagnosis and Drug Therapy of Prolactinoma},
  author={Enrica Ciccarelli and Franco Camanni},
  journal={Drugs},
  year={2012},
  volume={51},
  pages={954-965}
}
SummaryA prolactin-secreting pituitary tumour is the most frequent cause of hyperprolactinaemia that commonly occurs in clinical practice. Prolactinomas occur more frequently in women than in men and may differ in size, invasive growth and secretory activity. At presentation, macroadenomas are more frequently diagnosed in men. Specific immunohistochemical stains are necessary to prove the presence of prolactin in the tumour cells. The main investigations in the diagnosis of a prolactin… Expand
Pituitary Disorders
Pituitary diseases are relatively common entities in the general population. They include pituitary adenomas and hypopituitarism. Pituitary tumours can cause symptoms of mass effect and hormonalExpand
Managing prolactinoma during pregnancy
Objective: Prolactinomas are the most common pituitary tumors in pregnant women. We conducted this study on pregnant women with prolactinoma to determine their clinical symptoms and signs andExpand
MRI brain findings in patients with high serum prolactin levels
TLDR
Most of Patients had an abnormal MRI finding, showing that MRI screening should berecommended for Prolactin levels above 1000mIU/L, and microadenoma was the most common abnormality, having higher incidence in female patients. Expand
Managing Prolactinoma during Pregnancy Prolactinoma during Pregnancy Prolactinoma during Pregnancy Prolactinoma during Pregnancy
TLDR
Macroprolactinomas are more likely to enlarge during pregnancy than microprolActinomas, and conservative management was successfully done in all patients without surgery or medical therapy. Expand
Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist
TLDR
Patients who achieve TVR >25% with NP with 3 months of bromocriptine administration had a high possibility of showing good long-term response (TVR >50% withNP) to bromoriptine, and a higher dose of dopamine agonist (DA) or other DA should be considered for patients who achieveTVR <25% without NP. Expand
Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
TLDR
Patients who achieve TVRˁ25%with NP with 3 months of cabergoline administration had a high possibility of showing good long term response (TVR˃50% with NP) to cabergol, and a higher dose of dopamine agonist (DA) should be considered for patients who achieve televisionR˂25% without NP. Expand
Chapter 29 Multimodality Treatment of Pituitary Adenomas
Acromegaly is caused by excessive secretion of growth hormone (GH). The average annual incidence of acromegaly is approximately 3.3 per million, and the prevalence is approximately 60 per millionExpand
Pregnancy and pituitary disorders.
TLDR
The changes in anatomy and physiology of the pituitary gland during pregnancy are reviewed and Pituitary disorders namely Cushing's disease; acromegaly; prolactinoma; TSH-secreting, gonadotropin-producing, and clinically nonfunctioning adenomas; craniopharyngioma; and Sheehan's syndrome in relation to pregnancy are discussed. Expand
Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
TLDR
The preliminary findings show that rapid build-up of cabergoline doses increases its efficacy as well as rapidity of response in terms clinical improvement, normalization of serum prolactin and gonadal functions and reduction in tumour size, without compromising its safety in men with macroprolactinomas. Expand
Rapidly progressing giant invasive prolactinoma
TLDR
To the authors' knowledge, this is the first report of giant prolactinoma presenting with symptoms of sinusitis and nasopharyngeal tumour. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 68 REFERENCES
Giant invasive prolactinoma: a case report and review of nine further cases.
TLDR
In vitro studies of tissue from a patient with an exceptionally aggressive tumour which extended outside the skull and emerged within the internal jugular vein showed that although prolactin secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic levels of Prolactin mRNA, suggesting relative autonomy of prolACTin synthesis. Expand
Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
TLDR
There is insufficient evidence to recommend this drug as primary therapy for either prolactin-secreting or nonfunctional macroadenomas, but the drug may have potential as a preoperative adjunct to effect shrinkage of prolACTinomas and theoretically, at least, make excision easier and possibly more complete. Expand
Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone.
TLDR
It is concluded that pergolide reduces hypersecretion and shrinks most prolactin-secreting macroadenomas and in some patients long-term pergOLide therapy may be superior to surgery and x-ray treatment. Expand
Presence of Human Prolactin-Producing Adenomas and Bromocriptine: A Histological, Immunocytochemical, Ultrastructural, and Morphometric Study
TLDR
All four bromocriptine- treated patients demonstrated a reduction in serum PRL levels and tumor size on computed tomography, and patients 5 and 6 showed reexpansion of their tumors after drug withdrawal. Expand
Resistance to bromocriptine in prolactinomas.
TLDR
There was a very good correlation between the density of dopaminergic binding sites and maximal inhibition of adenylate cyclase activity in bromocriptine-responsive prolactinoma patients and resistant patients who had no tumor growth during therapy. Expand
Necrotic changes in prolactinomas after long term administration of bromocriptine.
TLDR
Long term bromocriptine treatment of patients with prolactinomas may result in necrosis of some adenoma cells in some patients. Expand
MULTIPLE INTRACRANIAL METASTASES FROM A PROLACTIN SECRETING PITUITARY TUMOUR
TLDR
A 28 year old man presented with partial hypopituitarism and signs of a pituitary tumour and died 12 years after the initial diagnosis, appearing to be the third well documented case of a metastasizing, prolactin secreting pituitARY tumour. Expand
Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study.
TLDR
The refinement of the transsphenoidal surgical approach to exploration of the sella turcica and the knowledge that amenorrheagalactorrhea and infertility can be reversed by selective surgical excision of a pituitary tumor has created a spectrum of patients now recognized as having hyperprolactinemia and PRL-secreting tumors. Expand
Pituitary tumors secreting growth hormone and prolactin.
TLDR
The recent advances in molecular biology, radioimmunoassay, neuroradiology, and transsphenoidal microneurosurgery techniques have greatly improved the understanding of the pathophysiology of these tumors, enhanced diagnostic accuracy, and led to newer medical and surgical therapeutic approaches. Expand
Histological classification of pituitary disease.
Morphological features of pituitary disease are classified according to increased and decreased hormone production to allow clinical correlation with pathological processes. Increased hormoneExpand
...
1
2
3
4
5
...